TransMedics Reports Strong Financial Growth in Q2 2025 with Increased Revenue and New Innovations TransMedics Group, Inc. announces impressive Q2 2025 financial results, highlighting a 38% revenue increase and new innovations in organ transplant therapy.

TransMedics Reports Strong Financial Growth in Q2 2025 with Increased Revenue and New Innovations #United_States #TransMedics #Andover #Organ_Care_System #NOP_Program

TransMedics Achieves Record Growth in 2024 Financial Performance Amid Transformative Advances in Organ Transplant Technology TransMedics reports impressive growth in revenue and net income for 2024, underlining their commitment to enhancing organ transplant technology and patient care.

TransMedics Achieves Record Growth in 2024 Financial Performance Amid Transformative Advances in Organ Transplant Technology #United_States #TransMedics #Andover #Organ_Care_System #OCS